|
1
|
Kumada H, Suzuki Y, Ikeda K, Toyota J,
Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et
al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b
infection. Hepatology. 59:2083–2091. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Omata M, Nishiguchi S, Ueno Y, Mochizuki
H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, et al:
Sofosbuvir plus ribavirin in Japanese patients with chronic
genotype 2 HCV infection: An open-label, phase 3 trial. J Viral
Hepat. 21:762–768. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chayama K, Notsumata K, Kurosaki M, Sato
K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA and
Kumada H: Randomized trial of interferon- and ribavirin-free
ombitasvir/paritaprevir/ritonavir in treatment-experienced
hepatitis C virus-infected patients. Hepatology. 61:1523–1532.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mizokami M, Yokosuka O, Takehara T,
Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F,
Yanase M, et al: Ledipasvir and sofosbuvir fixed-dose combination
with and without ribavirin for 12 weeks in treatment-naive and
previously treated Japanese patients with genotype 1 hepatitis C:
An open-label, randomised, phase 3 trial. Lancet Infect Dis.
15:645–653. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Suda G, Furusyo N, Toyoda H, Kawakami Y,
Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, et al:
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis
C virus infection: A nationwide retrospective study in Japan. J
Gastroenterol. 53:119–128. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Akuta N, Sezaki H, Suzuki F, Kawamura Y,
Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, et
al: Favorable efficacy of daclatasvir plus asunaprevir in treatment
of elderly Japanese patients infected with HCV genotype 1b aged 70
and older. J Med Virol. 89:91–98. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Falade-Nwulia O, Suarez-Cuervo C, Nelson
DR, Fried MW, Segal JB and Sulkowski MS: Oral direct-acting agent
therapy for hepatitis C virus infection: A systematic review. Ann
Intern Med. 166:637–648. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Backus LI, Belperio PS, Shahoumian TA and
Mole LA: . Impact of sustained virologic response with
direct-acting antiviral treatment on mortality in patients with
advanced liver disease. Hepatology. 69:487–497. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hauser P and Kern S: Psychiatric and
substance use disorders co-morbidities and hepatitis C: Diagnostic
and treatment implications. World J Hepatol. 7:1921–1935.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Leutscher PD, Lagging M, Buhl MR, Pedersen
C, Norkrans G, Langeland N, Mørch K, Färkkilä M, Hjerrild S,
Hellstrand K, et al: Evaluation of depression as a risk factor for
treatment failure in chronic hepatitis C. Hepatology. 52:430–435.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dalgard O, Bjøro K, Hellum K, Myrvang B,
Skaug K, Gutigard B, Bell H and Construct Group: Treatment of
chronic hepatitis C in injecting drug users: 5 years' follow-up.
Eur Addict Res. 8:45–49. 2002.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hosoda S, Takimura H, Shibayama M,
Kanamura H, Ikeda K and Kumada H: Psychiatric symptoms related to
interferon therapy for chronic hepatitis C: Clinical features and
prognosis. Psychiatry Clin Neurosci. 54:565–572. 2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zignego AL and Craxì A: Extrahepatic
manifestations of hepatitis C virus infection. Clin Liver Dis.
12:611–636. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Schaefer M, Capuron L, Friebe A,
Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D and
Pariante CM: Hepatitis C infection, antiviral treatment and mental
health: a European expert consensus statement. J Hepatol.
57:1379–1390. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cheng JS, Hu JH, Chang MY, Lin MS, Ku HP,
Chien RN and Chang ML: Hepatitis C-associated late-onset
schizophrenia: A nationwide, population-based cohort study. J
Psychiatry Neurosci. 46:E583–E591. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Back D, Belperio P, Bondin M, Negro F,
Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ and Marra F:
Efficacy and safety of glecaprevir/pibrentasvir in patients with
chronic HCV infection and psychiatric disorders: An integrated
analysis. J Viral Hepat. 26:951–960. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
de Gennaro N, Diella L, Monno L, Angarano
G, Milella M and Saracino A: Efficacy and tolerability of DAAs in
HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric
disorders. BMC Infect Dis. 20(196)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sackey B, Shults JG, Moore TA, Rogers R,
Mehvar M and King JG: Evaluating psychiatric outcomes associated
with direct-acting antiviral treatment in veterans with hepatitis C
infection. Ment Health Clin. 8:116–121. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Okano H, Murakami M, Asakawa H, Tsuruga S,
Tochio T, Kumazawa H, Sakuno T, Isono Y, Tanaka H, Matsusaki S, et
al: Acute hepatitis C virus infections in spouses: The utility of a
genetic analysis of the hepatitis C virus hypervariable region
sequence for identifying the infectious source. Arch Clin Med Case
Rep. 5:537–548. 2021.
|
|
20
|
Yamadate S and Nakayama T: The future
topics of discussion on JSCC recommended methods. Rinsho Byori.
64:544–549. 2016.PubMed/NCBI(In Japanese).
|
|
21
|
Tahata Y, Sakamori R and Takehara T:
Treatment progress and expansion in Japan: From interferon to
direct-acting antiviral. Glob Health Med. 3:321–334.
2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Phan SV: Medication adherence in patients
with schizophrenia. Int J Psychiatry Med. 51:211–219.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gaudiano BA, Weinstock LM and Miller IW:
Improving treatment adherence in bipolar disorder: A review of
current psychosocial treatment efficacy and recommendations for
future treatment development. Behav Modif. 32:267–301.
2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lazary J, Pogany L, De Las Cuevas C,
Villasante-Tezanos GA and De Leon J: Adherence to psychiatric
medications: Comparing patients with schizophrenia, bipolar
disorder and major depression. Neuropsychopharmacol Hung.
23:363–373. 2021.PubMed/NCBI
|
|
25
|
Sakamaki A, Kamimura K, Fukui N, Watanabe
H, Sakai N, Tominaga K, Mizuno K, Takamura M, Kawai H, Sugai T, et
al: A case report of psychiatric symptoms following direct-acting
antiviral and ribavirin combination therapy for chronic hepatitis C
in a patient with innate anxiety. BMC Gastroenterol.
19(85)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Braude MR, Phan T, Dev A and Sievert W:
Determinants of hepatitis C virus prevalence in people with serious
mental illness: A systematic review and meta-analysis. J Clin
Psychiatry. 83(21r14079)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sarin SK, Kumar M, Eslam M, George J, Al
Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, et al:
Liver diseases in the Asia-Pacific region: A lancet
gastroenterology & hepatology commission. Lancet Gastroenterol
Hepatol. 5:167–228. 2020.PubMed/NCBI View Article : Google Scholar
|
